Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

News Conference News VIVA 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

September 14, 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

September 13, 2017

Iliac Artery Occlusions Best Addressed by Self-Expanding Stents: ICE Trial

News Daily News

Iliac Artery Occlusions Best Addressed by Self-Expanding Stents: ICE Trial

August 25, 2017

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

August 03, 2017

News Industry News

Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting

April 26, 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

February 17, 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

News Conference News ISET 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

February 15, 2017

Gains in Carotid Stenting Technology Could Increase the Treatment’s Appeal

News Conference News ISET 2017

Gains in Carotid Stenting Technology Could Increase the Treatment’s Appeal

February 13, 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

News Conference News ISET 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

February 07, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.